Possible target found for idiopathic pulmonary fibrosis treatment
A new study shows that using therapeutic antibodies to block the interleukin-11 protein can reverse idiopathic pulmonary fibrosis.
List view / Grid view
A new study shows that using therapeutic antibodies to block the interleukin-11 protein can reverse idiopathic pulmonary fibrosis.
Researchers have found that the FHL1 protein plays a key role in chikungunya virus replication and pathogenesis.
A study using high-throughput screening has revealed some promising compounds that could be used in future cancer treatments.
Researchers have discovered the process that enables glioblastomas to avoid the effects of the immune system, presenting an immuno-oncology target.
A new method to reactivate 'tumour suppressor' genes switched off by cancer cells could lead to new targeted biotherapies for cancer.
A new platform brings together genome editing with magnetic cell sorting to reveal new drug targets for cancer and regenerative medicine.
A team has discovered that fungi use the Diels-Alder reaction to assemble new compounds that have potential pharmaceutical uses.
A new study shows the ways in which epigenetic mechanisms control the activity of genes and may have an impact on the future treatment of certain cancers.
Almost all animal subjects exposed to genital herpes were protected by the novel vaccine.
A study has discovered the mechanism behind NSCLC resistance to chemotherapy, which could improve treatment strategies for the condition.
A mechanism has been identified which regulates the release of insulin from β-cells and could be used to develop new treatments for type 2 diabetes.
A method designed to genetically alter laboratory mice can also be used to produce personalised animal models of an aggressive type of malignant brain cancer in children.
Researchers have discovered neurons send electrical signals to glioblastoma tumours, causing them to grow but have also identified methods of prevention in models.
A new target has been identified for the treatment of heart failure, heart attack, stroke and neurodegeneration.
A new platform combines AI, flow chemistry and robotics to minimise the need for human intervention in the synthesis process.